UBS initiated coverage of Jasper Therapeutics (JSPR) with a Buy rating and $38 price target The firm says KIT inhibition is “differentiated in the underpenetrated” chronic spontaneous urticaria space. UBS sees a $3.8B market opportunity in CSU.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Largest borrow rate increases among liquid names
- Jasper Therapeutics price target lowered to $48 from $68 at RBC Capital
- Jasper Therapeutics price target lowered to $64 from $90 at BTIG
- JMP Securities healthcare analysts hold an analyst/industry conference call
- Jasper BEACON data ‘net positive,’ says BMO Capital